Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Sangamo Therapeutics patents

Patents where

Current Assignee

Name

Sangamo Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9873894 Methods and compositions for treatment of a genetic condition	Patent 9873894 was granted and assigned to Sangamo Therapeutics on January, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9873894	January 23, 2018
‌ US Patent 11311574 Methods and compositions for targeted cleavage and recombination	Patent 11311574 was granted and assigned to Sangamo Therapeutics on April, 2022 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	11311574	April 26, 2022
‌ US Patent 11352631 Targeted disruption of the T cell receptor			Sangamo Therapeutics	United States Patent and Trademark Office	11352631	June 7, 2022
‌ US Patent 9782437 Methods and compositions for targeted cleavage and recombination	Patent 9782437 was granted and assigned to Sangamo Therapeutics on October, 2017 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9782437	October 10, 2017
‌ US Patent 11648267 Methods and compositions for gene inactivation	Patent 11648267 was granted and assigned to Sangamo Therapeutics on May, 2023 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	11648267	May 16, 2023
‌ US Patent 11285175 Targeted disruption of the MHC cell receptor	Patent 11285175 was granted and assigned to Sangamo Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	11285175	March 29, 2022
‌ US Patent 9902974 Methods and compositions for treatment of a genetic condition	Patent 9902974 was granted and assigned to Sangamo Therapeutics on February, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9902974	February 27, 2018
‌ US Patent 10196651 Methods and compositions for treatment of a genetic condition	Patent 10196651 was granted and assigned to Sangamo Therapeutics on February, 2019 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	10196651	February 5, 2019
‌ US Patent 9970028 Targeted genomic modification with partially single-stranded donor molecules	Patent 9970028 was granted and assigned to Sangamo Therapeutics on May, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9970028	May 15, 2018
‌ US Patent 11512287 Targeted disruption of T cell and/or HLA receptors		Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	11512287	November 29, 2022
‌ US Patent 11492643 Methods and compositions for treatment of a genetic condition	Patent 11492643 was granted and assigned to Sangamo Therapeutics on November, 2022 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	11492643	November 8, 2022
‌ US Patent 10113207 Methods and compositions for targeted single-stranded cleavage and targeted integration	Patent 10113207 was granted and assigned to Sangamo Therapeutics on October, 2018 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	10113207	October 30, 2018
‌ US Patent 9833479 Gene correction of SCID-related genes in hematopoietic stem and progenitor cells	Patent 9833479 was granted and assigned to Sangamo Therapeutics on December, 2017 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	9833479	December 5, 2017
‌ US Patent 10968261 Methods and compositions for genome engineering	Patent 10968261 was granted and assigned to Sangamo Therapeutics on April, 2021 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	10968261	April 6, 2021
‌ US Patent 10081661 Methods and compositions for genome engineering	Patent 10081661 was granted and assigned to Sangamo Therapeutics on September, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	10081661	September 25, 2018
‌ US Patent 10407476 Methods and compositions for treating hemophilia	Patent 10407476 was granted and assigned to Sangamo Therapeutics on September, 2019 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	10407476	September 10, 2019
‌ US Patent 11401512 Engineered target specific nucleases	Patent 11401512 was granted and assigned to Sangamo Therapeutics on August, 2022 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	11401512	August 2, 2022
‌ US Patent 9816074 Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells	Patent 9816074 was granted and assigned to Sangamo Therapeutics on November, 2017 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9816074	November 14, 2017
‌ US Patent 11634463 Methods and compositions for treating hemophilia	Patent 11634463 was granted and assigned to Sangamo Therapeutics on April, 2023 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	11634463	April 25, 2023
‌ US Patent 11608492 Compositions for linking DNA-binding domains and cleavage domains	Patent 11608492 was granted and assigned to Sangamo Therapeutics on March, 2023 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	11608492	March 21, 2023
‌ US Patent 10046028 Methods and compositions for modulating PD1	Patent 10046028 was granted and assigned to Sangamo Therapeutics on August, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	10046028	August 14, 2018
‌ US Patent 9957526 Delivery methods and compositions for nuclease-mediated genome engineering	Patent 9957526 was granted and assigned to Sangamo Therapeutics on May, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9957526	May 1, 2018
‌ US Patent 9970001 Methods and compositions for nuclease design	Patent 9970001 was granted and assigned to Sangamo Therapeutics on May, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9970001	May 15, 2018
‌ US Patent 10179918 Methods and compositions for increasing transgene activity	Patent 10179918 was granted and assigned to Sangamo Therapeutics on January, 2019 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	10179918	January 15, 2019
‌ US Patent 10143760 Liver-specific constructs, factor VIII expression cassettes and methods of use thereof	Patent 10143760 was granted and assigned to Sangamo Therapeutics on December, 2018 by the United States Patent and Trademark Office.	Sangamo Therapeutics	Sangamo Therapeutics	United States Patent and Trademark Office	10143760	December 4, 2018

Results per page:

88 results

0 selected

88 results

0 selected